BioWorld

Feb. 18, 2005

Dendreon Shows Survival Benefit In Phase III Study Of Provenge

A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today) Read More

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

'Matchmaker' SNP Study Paves Way For Pharmacogenomics

BioCryst Raises $23.9M Privately To Fund Lead Clinical Products

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...